LifeX Ventures

LifeX Ventures invests from Seed through Growth stages, with a focus on early-stage companies. The firm looks for AI-native platforms in longevity science that have moved past initial academic proof-of-concept and are ready for translational development. This stage-agnostic flexibility within the early-to-growth range allows LifeX to support companies from first institutional capital through later rounds.

The firm believes that artificial intelligence—specifically machine learning applied to biological data—will compress the timeline for discovering and validating longevity interventions. LifeX focuses on companies building the core computational engines for aging biology, including AI-driven drug discovery platforms, digital biomarker tools, and personalized health applications that target the fundamental biology of aging rather than isolated diseases.

LifeX Ventures does not invest in general healthcare services, traditional pharmaceuticals without an AI-native component, medical devices without computational differentiation, or consumer wellness products. The firm's narrow mandate excludes any company where the primary value proposition is not a machine learning model or data platform applied to longevity biology. This sector negative screen is central to its concentrated portfolio approach.

Pittsburgh's proximity to Carnegie Mellon University—a globally dominant institution in artificial intelligence and machine learning research—is a structural sourcing advantage for LifeX. The city's growing biotech ecosystem and lower cost structure compared to coastal biotech hubs allow the firm to access technical talent and academic spinouts in computational biology at favorable valuations. This geographic posture is integral to the firm's deal-flow strategy.